EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieVergleichsstudie

Pharmacokinetic and Bioequivalence Evaluation of Two Lercanidipine Hydrochloride Tablets in Healthy Chinese Volunteers

Biao Sun, Li Zhao, Fangliang Gan, Qiong Zhan

Clinical Pharmacology in Drug Development · 2026-03 · 15 (3)

DOI: 10.1002/cpdd.70045 ↗

At a glance

Randomisierte kontrollierte Studie in Clinical Pharmacology in Drug Development, published online on 2026-03-01. Written by Biao Sun and 3 co-authors. Institution: Department of Pharmacy, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, P. R. China. Major MEDLINE topics: Antihypertensive Agents, Calcium Channel Blockers, Dihydropyridines. 18 references. Funded by: Fujian Boro Pharmaceutical Research Co., Ltd.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Lercanidipine hydrochloride is a third‐generation dihydropyridine calcium channel blocker used to treat mild‐to‐moderate hypertension. The aim of this study is to compare the pharmacokinetic characteristics of lercanidipine hydrochloride tablets (10 mg) in healthy Chinese volunteers after oral administration under fasting conditions with those of a reference formulation, and to evaluate the bioequivalence and safety of the two formulations. A validated liquid chromatography‐tandem mass spectrometry method was established to determine the plasma concentration of lercanidipine. Phoenix WinNonlin software (version 7.0) was used to calculate pharmacokinetic parameters based on plasma drug concentration–time data. The geometric mean ratios and 90% confidence intervals of C max , AUC 0–t , and AUC 0–∞ for the test formulation relative to the reference formulation were 110.37% (99.96%–121.86%), 106.81% (99.65%–114.49%), and 106.91% (99.86%–114.45%), respectively, all within the range of 80.00%–125.00%. The test formulation met the bioequivalence acceptance criteria and was well tolerated by healthy Chinese volunteers under fasting conditions.

Subjects

MeSH terms (MEDLINE)

Antihypertensive AgentsCalcium Channel BlockersDihydropyridinesAdultFemaleHumansMaleYoung AdultAdministration, OralArea Under CurveChromatography, LiquidCross-Over StudiesFastingHealthy VolunteersTabletsTandem Mass SpectrometryTherapeutic EquivalencyEast Asian People

Author keywords

bioequivalencehypertensionlercanidipine hydrochloride tabletspharmacokinetic

Substances

Antihypertensive AgentsCalcium Channel BlockersDihydropyridineslercanidipineTablets

Authors and institutions

  • Department of Pharmacy, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, P. R. China.
  • Department of Gynecology, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, P. R. China.
  • Phase I Clinical Trial Unit, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, P. R. China.

Funding

  • Fujian Boro Pharmaceutical Research Co., Ltd

Cite

APA

Sun, B., Zhao, L., Gan, F., & Zhan, Q. (2026). Pharmacokinetic and Bioequivalence Evaluation of Two Lercanidipine Hydrochloride Tablets in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development, 15(3). https://doi.org/10.1002/cpdd.70045

Vancouver

Sun B, Zhao L, Gan F, Zhan Q. Pharmacokinetic and Bioequivalence Evaluation of Two Lercanidipine Hydrochloride Tablets in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. 2026;15(3). doi:10.1002/cpdd.70045

BibTeX
@article{Sun2026,
  author = {Sun, Biao and Zhao, Li and Gan, Fangliang and Zhan, Qiong},
  title = {Pharmacokinetic and Bioequivalence Evaluation of Two Lercanidipine Hydrochloride Tablets in Healthy Chinese Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cpdd.70045}
}
Start for free →